Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus monotherapy for idiopathic membranous nephropathy
ChiCTR2000032422Phase 4Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jul 2020
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tacrolimus in idiopathic membranous glomerulonephritis (IMG) (2 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoints: Serum creatinine, Serum albumin and 1 more. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
tacrolimus
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on ChiCTR2000032422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032422.